This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
by Zacks Equity Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $89.92, marking a +0.46% move from the previous day.
AstraZeneca to End Phase III Study on Fish Oil Heart Drug
by Zacks Equity Research
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration
by Zacks Equity Research
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
by Zacks Equity Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study
by Zacks Equity Research
Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
by Kinjel Shah
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio meets the primary goal in a late-stage study evaluating it as a first-line maintenance therapy for metastatic urothelial carcinoma, a form of bladder cancer.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $91.64, moving +0.42% from the previous trading session.
Leap Therapeutics Surges on License Agreement With BieGene
by Zacks Equity Research
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
Amgen Stock Up in a Year on Pipeline & Biosimilar Progress
by Zacks Equity Research
Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
4 Reasons Why You Should Invest in J&J (JNJ) Stock in 2020
by Zacks Equity Research
Here are four reasons which investors may consider while investing in J&J's (JNJ) stock.
Novo Nordisk's Shares Up in a Year on Pipeline Progress
by Zacks Equity Research
Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $90.92, marking a -0.12% move from the previous day.
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
5 Stocks From Top-Ranked Industries Ready to Explode in 2020
by Zacks Equity Research
These top-ranked industries stocks are witnessing positive earnings estimate revisions for 2020 and are likely to boost portfolio returns.
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck